240 results
8-K
EX-99.1
BIIB
Biogen Inc
13 Feb 24
Biogen reports fourth quarter and full year 2023 results and expects return to Non-GAAP EPS growth in 2024
7:07am
, will continue to be classified as a component of revenue. Biogen will now present its 50% share of all global pre- and post-commercialization sales … of LEQEMBI product revenue, net and cost of sales, including royalties, will continue to be classified as a component of revenue. Biogen will now
8-K
EX-99.1
wgoid
8 Nov 23
Biogen reports third quarter 2023 results and updates full year 2023 guidance
7:02am
8-K
EX-10.1
rk8rzwry
1 Sep 23
Entry into a Material Definitive Agreement
4:36pm
DEFA14A
wc26k
31 Jul 23
Additional proxy soliciting materials
7:02am
8-K
EX-2.1
omaplni
31 Jul 23
Entry into a Material Definitive Agreement
7:00am